We are live on ! Find out more
PRLD icon

Prelude Therapeutics
PRLD

68 hedge funds and large institutions have $235M invested in Prelude Therapeutics in 2022 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 19 increasing their positions, 25 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

7,500% more call options, than puts

Call options by funds: $1.52M | Put options by funds: $20K

9% less funds holding

Funds holding: 75 → 68 (-7)

24% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 25

26.6% less ownership

Funds ownership: 98.22% → 71.61% (-27%)

37% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 19

46% less capital invested

Capital invested by funds: $438M → $235M (-$202M)

Holders
68
Holders Change
-7
Holders Change %
-9.33%
% of All Funds
1.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
19
Reduced
25
Closed
19
Calls
$1.52M
Puts
$20K
Net Calls
+$1.5M
Net Calls Change
+$1.47M

Top Buyers

Rank Fund Capital Flow
1
UBS AM
UBS AM
Illinois
+$8.31M
2
BlackRock
BlackRock
New York
+$1.42M
3
State of Wisconsin Investment Board
State of Wisconsin Investment Board
Wisconsin
+$560K
4
Bank of America
Bank of America
North Carolina
+$519K
5
IA
IndexIQ Advisors
New York
+$519K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$5.19M
2
Millennium Management
Millennium Management
New York
-$3.7M
3
Morgan Stanley
Morgan Stanley
New York
-$2.74M
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$1.62M
5
CSS
Cubist Systematic Strategies
Connecticut
-$1.45M
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
51
Tower Research Capital (TRC)
New York
$16K -$27.3K -2,985 -56%
SO
52
STRS Ohio
Ohio
$15K – – –
Citigroup
53
Citigroup
New York
$12K -$21.6K -2,359 -58%
BDWM
54
Brewin Dolphin Wealth Management
Ireland
$12K – – –
AB
55
Amalgamated Bank
New York
$12K +$16.1K +1,764 New
AF
56
Amalgamated Financial
New York
$12K +$16.1K +1,764 New
LC
57
Lindbrook Capital
California
$11K +$13.5K +1,471 +1,616%
Simplex Trading
58
Simplex Trading
Illinois
$10K +$14.3K +1,561 New
S
59
SignatureFD
Georgia
$7K +$6.99K +764 +335%
AIP
60
Ameritas Investment Partners
Nebraska
$5K – – –
DB
61
Dravo Bay
Delaware
$4.49K +$5.95K +650 New
US Bancorp
62
US Bancorp
Minnesota
$4K +$3.88K +424 +233%
Osaic Holdings
63
Osaic Holdings
Arizona
$2K +$229 +25 +7%
Wells Fargo
64
Wells Fargo
California
$1K -$27.9K -3,052 -97%
UBS Group
65
UBS Group
Switzerland
$1K -$16.1K -1,755 -91%
Daiwa Securities Group
66
Daiwa Securities Group
Japan
$1K – – –
Jacobs Levy Equity Management
67
Jacobs Levy Equity Management
New Jersey
– -$1.62M -130,280 Closed
CSS
68
Cubist Systematic Strategies
Connecticut
– -$1.45M -116,303 Closed
HF
69
HRT Financial
New York
– -$1.42M -114,249 Closed
PCM
70
Pinz Capital Management
New York
– -$545K -43,800 Closed
Walleye Capital
71
Walleye Capital
New York
– -$522K -41,954 Closed
JF
72
Jump Financial
Illinois
– -$459K -36,900 Closed
Susquehanna International Group
73
Susquehanna International Group
Pennsylvania
– -$268K -29,275 Closed
Norges Bank
74
Norges Bank
Norway
– -$311K -25,000 Closed
Qube Research & Technologies (QRT)
75
Qube Research & Technologies (QRT)
United Kingdom
– -$291K -23,384 Closed
1 2
3
4

PRLD Hedge Fund Activity: Q1 2022 in Review

68 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q1 2022, worth a combined $235M — down 46% from $438M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of PRLD and 12 opened new positions — a net loss of 7 holders — while 25 trimmed existing stakes and 19 added.

The largest buyer was UBS AM, adding an estimated $8.31M. The largest seller was Fidelity Investments, cutting an estimated $5.19M.

  • 68 institutional investors held Prelude Therapeutics (PRLD) as of Q1 2022, down from 75 in Q4 2021.
  • Funds reported $235M of Prelude Therapeutics stock for Q1 2022, down 46% quarter-over-quarter.
  • 12 funds opened new Prelude Therapeutics positions in Q1 2022 and 19 closed out, a net change of -7 holders.
  • The largest Prelude Therapeutics buyer in Q1 2022 was UBS AM, an estimated $8.31M added.
  • The largest Prelude Therapeutics seller in Q1 2022 was Fidelity Investments, an estimated $5.19M sold.

Based on aggregated 13F filings for Q1 2022.